CD44 and cancer: Adding melatonin to neoadjuvant chemotherapy reduced the levels of miR-210 and CD44, which are markers of hypoxia, cancer stemness, therapy resistance, angiogenesis, and recurrence; however, the reduction was not statistically significant compared to the placebo cohort